This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Sun May 19, 2013 3:52 pm


All times are UTC - 8 hours [ DST ]




Post new topic Reply to topic  [ 2 posts ] 
Author Message
PostPosted: Mon Oct 15, 2012 11:45 am 
Offline
Family Elder
User avatar

Joined: Wed Oct 14, 2009 3:00 pm
Posts: 1681
Image

Multiple sclerosis appears to be joining psoriasis and rheumatoid arthritis as potential indications for secukinumab (AIN457), results of a small trial suggested.

The drug, which neutralizes interleukin-17a, significantly lowered MS-type brain lesions and showed a trend toward reduced relapse rates in a 6-month, placebo-controlled trial in 73 patients, said Eva Havrdová, MD, PhD, of Charles University in Prague.

Speaking at a late-breaking abstract session here at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis, Havrdová characterised the results as "proof of concept" that would merit larger and longer trials.

The investigational drug has already shown positive results in psoriasis and rheumatoid arthritis.

By binding to IL-17A, it prevents the cytokine from binding to its receptors, which, in turn, inhibits release of a host of other proinflammatory proteins -- hence, the potential to treat a range of autoimmune conditions. However, in multiple sclerosis, IL-17 species have only recently attracted attention as a potential therapeutic target.

With secukinumab already tested for safety and tolerability in other disorders, Havrdová and colleagues -- as well as the drug's developer, Novartis -- decided the time was right for a small efficacy study in relapsing-remitting MS patients.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2479

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis


Top
 Profile  
 
PostPosted: Wed Oct 17, 2012 1:57 pm 
Offline
Volunteer Moderator

Joined: Sat Mar 11, 2006 4:00 pm
Posts: 7607
link to abstract

Positive proof of concept of AIN457, an antibody against interleukin-17A, in relapsing-remitting multiple sclerosis
http://registration.akm.ch/einsicht.php ... KEN_ID=900

_________________
my approach: no meds so far - just balanced whole foods (partial 'paleo', much less outright elimination), science, supplements, & bloodwork
my regimen - www.thisisms.com/ftopict-2489.html
www.whfoods.com, www.nutritiondata.com


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 2 posts ] 

All times are UTC - 8 hours [ DST ]


Related topics
 Topics   Author   Replies   Views   Last post 
There are no new unread posts for this topic. Research shines light on childhood multiple sclerosis

squiffy2

2

314

Mon Jun 18, 2012 4:19 pm

lyndacarol View the latest post

There are no new unread posts for this topic. Myelin Repair Drug Trial - Biogen Starts Human Trial..

ElMarino

5

1389

Wed Jan 27, 2010 6:01 pm

Absentee View the latest post

There are no new unread posts for this topic. Trial funding

billf

3

1469

Wed Jan 26, 2005 4:40 am

JFH View the latest post

There are no new unread posts for this topic. Tryptophan trial

bromley

2

1079

Thu Nov 10, 2005 3:32 pm

Melody View the latest post

There are no new unread posts for this topic. UK cannabis trial

bromley

0

963

Fri May 26, 2006 1:01 pm

bromley View the latest post

 


Who is online

Users browsing this forum: No registered users


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to: